Inovio Pharmaceuticals(US:INO) Prnewswire·2026-03-11 13:20Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, reminding investors of the April 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [1] Group 1: Legal Action and Allegations - The complaint alleges that Inovio and its executives violated federal securities laws by making false and/or misleading statements and failing to disclose deficiencies in the manufacturing of Inovio's CELLECTRA device [1] - It is claimed that Inovio is unlikely to submit the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 due to these deficiencies [1] - The company reportedly lacks sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [1] Group 2: Stock Market Impact - Following the FDA's announcement that it accepted Inovio's BLA for INO-3107 on a standard review timeline, Inovio's stock price fell by $0.56 per share, or 24.45%, closing at $1.73 per share on December 29, 2025 [1] Group 3: Class Action Participation - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will direct and oversee the litigation on behalf of the class members [1] - Any member of the putative class may move the Court to serve as lead plaintiff or choose to remain an absent class member, with their ability to share in any recovery unaffected by this decision [1]